TRANSLATE

The mpn Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the mpn Hub cannot guarantee the accuracy of translated content. The mpn and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

The MPN Hub is an independent medical education platform, sponsored by AOP Health and GSK, and supported through an educational grant from Bristol Myers Squibb. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.

Now you can support HCPs in making informed decisions for their patients

Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.

Find out more

Clinical trial club | NCT03194542: Key efficacy and safety findings

Featured:

Jean-Jacques KiladjianJean-Jacques KiladjianAaron GerdsAaron Gerds

Aug 14, 2023


Video series

During the clinical trial club live webinar, "NCT03194542 trial: Luspatercept for the treatment of patients with anemic myelofibrosis," lead investigator Aaron Gerds presented key efficacy and safety data from the trial. He highlighted the strengths and limitations of the study, and future directions for the treatment of myelofibrosis.

Please indicate your level of agreement with the following statements:

The content was clear and easy to understand

The content addressed the learning objectives

The content was relevant to my practice

I will change my clinical practice as a result of this content